Radiation Therapy Plus Doxorubicin in Treating Patients With Resectable Primary or Recurrent Retroperitoneal Soft Tissue Sarcoma

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

July 31, 1997

Primary Completion Date

July 31, 2001

Study Completion Date

October 31, 2009

Conditions
Sarcoma
Interventions
DRUG

Doxorubicin hydrochloride (DOX)

Doxorubicin IV bolus followed immediately by IV over 4 days every week for 5 weeks concurrently with external beam radiotherapy 5 days a week for 4 weeks.

PROCEDURE

Conventional surgery

Surgical resection of primary tumor and all adjacent gross disease approximately 6 weeks after chemoradiotherapy

RADIATION

Intraoperative radiation therapy (IORT)

Intraoperative radiotherapy (IORT) to tumor bed if all gross disease has been resected and if area of maximal tumor adherence to retroperitoneum can be encompassed within a single IORT field (maximum 15 cm).

RADIATION

Radiation Therapy (RT)

5 days a week for 4 weeks

Trial Locations (1)

77030-4009

University of Texas - MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT00004123 - Radiation Therapy Plus Doxorubicin in Treating Patients With Resectable Primary or Recurrent Retroperitoneal Soft Tissue Sarcoma | Biotech Hunter | Biotech Hunter